Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jan 17, 2020 at 12:32 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,730
    Likes Received:
    3
    via The UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the NHS because it is too expensive.

    Despite that decision, NICE says there’s little doubt that ‘histology independent’ drugs like Vitrakvi (entrectinib) – which treat cancer based on the presence of a genetic mutation rather than its location in the body – have the potential to be ‘game changing’ treatments for cancer.

    article source